Involving Cholesterol Patents (Class 435/11)
  • Patent number: 10717863
    Abstract: A block copolymer of the formula Rf-PEG-PAA is disclosed, where Rf comprises a perfluoroalkyl group having at least 3 carbon atoms, bound to an ether oxygen atom directly or through a substituted or unsubstituted alkylene group, PEG is a poly(alkylene glycol) unit having a weight average molecular weight or number average molecular weight of from 1 to 20 kDa, and PAA is one or more poly([meth]acrylic acid) units having a total weight average molecular weight or number average molecular weight of from 0.3 to 10 kDa. A polymer mixture including the block copolymer, a co-hydrogel and a drug delivery vehicle including the polymer mixture, and methods of synthesizing the block copolymer, forming a sol-gel two-phase co-hydrogel, forming a drug delivery vehicle, and delivering a drug to a patient in need thereof are also disclosed.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 21, 2020
    Inventors: Yong Ba, Yang Sun
  • Patent number: 10665349
    Abstract: Methods and model equations are provided for predicting a risk of a subject who experiences adverse medical events associated with the weather, of experiencing a new-onset event. Methods include a) identifying a climate region of interest; b) collecting daily mean barometric pressure (BP) data for a time frame and dividing the days of the time frame into at least upper, middle and lower quantile BP days to identify the upper quantile BP days.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: May 26, 2020
    Assignees: University of Cincinnati, Errex, Inc.
    Inventors: Vincent Martin, Linda Levin, Mark Russell Simmons, Robert Allen Nicholson, Albert Peterlin
  • Patent number: 10501773
    Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: December 10, 2019
    Assignee: Haemonetics Corporation
    Inventors: Fowzia S. Zaman, Marc Doubleday
  • Patent number: 10436798
    Abstract: The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: October 8, 2019
    Assignees: Metanomics GmbH, Ruprecht-Karls-Universität Heidelberg
    Inventors: Regina Reszka, Jens Fuhrmann, Jürgen Kastler, Bianca Bethan, Martin Kluttig, Hugo A. Katus, Norbert Frey, Johanna Wolf, Tanja Weis
  • Patent number: 10317396
    Abstract: The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: June 11, 2019
    Assignee: West Virginia University
    Inventors: Florin V. Chirila, Tapan Kumar Khan, Daniel L. Alkon
  • Patent number: 10111937
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: October 30, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Patent number: 10048251
    Abstract: The present invention relates to a strip for an improved lateral flow assay of a biological sample on a single plane and a lateral flow chromatography assay using a test device containing the same. The strip of the present invention consists of a single-pad, which can improve lateral flow assay by providing an easy and simple procedure and clear visual reading. The strip of the present invention is consisted of sample application (sample) zone and reactant-resultant zone where the reaction mixture is deposited (reactant) are all on a same plane. In addition, the present invention provides a chromatographic method wherein hemoglobin is separated from analyte by a differential chromatography on the solid phase. Any interference of detection of the result by hemoglobin is removed by the present invention. The present invention provides advantages including an easy and simple procedure with a quick and clear response.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: August 14, 2018
    Assignee: ACCESS BIO, INC.
    Inventors: Hyeon Suk Kim, Tae-Hee Koo, Young Ho Choi
  • Patent number: 10031145
    Abstract: Disclosed is a method for quantifying HDL2 cholesterol in a test sample without requiring laborious operations. The method for quantifying cholesterol comprises allowing phospholipase to act on HDL to quantify cholesterol. Also disclosed is a method comprising: a first step of transferring cholesterols other than high-density lipoproteins in a test sample to the outside of the reaction system; and a second step of quantifying high-density lipoprotein 2 cholesterol among the high-density lipoproteins remaining in the reaction system; wherein, by performing the second step by the above method, high-density lipoprotein 2 cholesterol in the test sample can be quantified.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: July 24, 2018
    Assignee: Denka Seiken Co., Ltd.
    Inventors: Maiko Higuchi, Yasuki Itoh
  • Patent number: 10018641
    Abstract: Disclosed is the provision of a method for quantifying HDL3 in a test sample without requiring a laborious operation. The method for quantifying cholesterol in high-density lipoprotein 3 comprises allowing a surfactant(s) which specifically react(s) with a high-density lipoprotein 3 to react with a test sample and quantifying cholesterol, and the surfactant(s) is(are) at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ether and polyoxyethylene styrenated phenyl ether.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: July 10, 2018
    Assignee: DENKA SEIKEN CO., LTD.
    Inventors: Noriyuki Sato, Yuhko Hirao, Yasuki Itoh
  • Patent number: 9902951
    Abstract: A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: February 27, 2018
    Assignees: Illumina, Inc., Illumina Cambridge Limited
    Inventors: Eric H. Kawashima, Laurent Farinelli, Pascal Mayer
  • Patent number: 9828624
    Abstract: Methods of the invention involve determining a patient's compliance with a cholesterol lowering therapy. In certain aspects, the invention provides methods that involve conducting a first assay to determine a cholesterol biomarker level in a first sample from a patient prior to the patient undergoing a cholesterol lowering therapy. The methods may also involve conducting a second assay to determine a cholesterol level in a second sample obtained from the patient after the patient has started undergoing a cholesterol lowering therapy. Additionally, the methods involve associating the cholesterol level and the cholesterol biomarker level in which the association allows for the determination of the patient's compliance with the cholesterol lowering therapy.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: November 28, 2017
    Assignee: BOSTON HEART DIAGNOSTICS CORPORATION
    Inventor: Ernst J. Schaefer
  • Patent number: 9778271
    Abstract: The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin A1c or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: October 3, 2017
    Assignee: Abbott Point of Care Inc.
    Inventor: Cary James Miller
  • Patent number: 9778251
    Abstract: The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin Alc or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: October 3, 2017
    Assignee: Abbott Point of Care Inc.
    Inventor: Cary James Miller
  • Patent number: 9702807
    Abstract: Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry. A method and apparatus are provided for measuring the number of lipoprotein particles in a sample using photometry.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: July 11, 2017
    Assignee: Ningbo Alabama, LLC
    Inventor: Krishnaji R Kulkarni
  • Patent number: 9695464
    Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: July 4, 2017
    Assignee: AXIS-SHIELD AS
    Inventors: Arne Ludvig Faaren, Frank Frantzen, Arne Kristian Nordhei, Erling Sundrehagen, Lars Ørning
  • Patent number: 9678081
    Abstract: The chromatography method includes a step of forming a composite with a test substance and a labeling substance containing a metal modified by a first binding substance of the test substance and then developing the composite on an insoluble carrier; a step of capturing the test substance and the labeling substance in a detection site on the insoluble carrier including a second binding substance of the test substance or a substance having a binding property to the first binding substance of the test substance; and a step of amplifying the captured labeling substance using a first amplification reagent and a second amplification reagent to detect the test substance.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: June 13, 2017
    Assignee: FUJIFILM Corporation
    Inventor: Atsuhiko Wada
  • Patent number: 9663816
    Abstract: Provided is a measuring method of a component to be measured in a specimen while suppressing an influence of bilirubin. A measuring method of a component to be measured, comprising converting the component to be measured in the specimen to hydrogen peroxide through an enzymatic reaction, reacting the formed hydrogen peroxide with an oxidative-coloring chromogen in the presence of a peroxidase, and measuring an absorbance of the colored reaction solution to thereby determine the component to be measured, wherein a fatty acid or a salt thereof coexists. The measuring method of a component to be measured in a specimen according to the present invention is useful in clinical diagnosis.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: May 30, 2017
    Assignee: KYOWA MEDEX CO., LTD.
    Inventors: Hideyuki Kuwata, Tomoko Aratake, Kenta Kinjo
  • Patent number: 9494605
    Abstract: The present invention relates in particular to methods of detecting predisposition to or diagnosis and/or prognosis of Charcot-Marie-Tooth (CMT) and related disorders. More specifically, the invention relates to development, validation and application of new biomarkers, which can be used for detecting the presence or risk of CMT disease and related disorders. In particular, the present invention relates to metabolite, lipid, carbohydrate and proteinaceous biomarkers that can be measured in biological body fluids and easily available extracts of biopsies, which can be used to aid in the detection, prediction of drug treatment and follow up of this treatment of neurodegenerative disorders, including CMT disease. The present invention also relates to methods for identification of CMT disease subtypes, assessing the responsiveness to the treatments and the efficacy of treatments in subjects having CMT or a related disorder.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: November 15, 2016
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin
  • Patent number: 9493433
    Abstract: Described is a method for preserving an aqueous solution comprising a leuco chromogen, comprising adding at least one compound selected from the group consisting of polyoxyethylene alkylamine and polyoxyethylene alkenylamine to the aqueous solution containing a leuco chromogen, and a method for stabilizing a leuco chromogen, comprising allowing the leuco chromogen to coexist in an aqueous solution comprising at least one compound selected from the group consisting of polyoxyethylene alkylamine and polyoxyethylene alkenylamine.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: November 15, 2016
    Assignee: KYOWA MEDEX CO., LTD.
    Inventors: Haruyo Soya, Tomomi Murakami, Haruki Tsunoda, Yu Ohsugi, Ayako Yoda, Masashi Matsushita
  • Patent number: 9470698
    Abstract: In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including POE-POP-POE block copolymer, a surfactant, and a reflectivity changing reactant, the POE-POP-POE block copolymers solubilizing essentially only non-LDL cholesterol analytes, the non-LDL cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: October 18, 2016
    Assignee: Polymer Technology Systems, Inc.
    Inventors: Timothy Riley, Aniruddha Patwardhan, Frank LaDuca
  • Patent number: 9412572
    Abstract: Certain embodiments described herein are directed to sample holders that can be used to retain a sample support effective for use in direct sample analysis. In some embodiments, the sample support can include a first and a second plate with apertures to permit a sample to be analyzed using direct sample analysis.
    Type: Grant
    Filed: October 28, 2012
    Date of Patent: August 9, 2016
    Assignee: PerkinElmer Health Sciences, Inc.
    Inventors: Paul L St. Cyr, Michael L. DelVecchio, Leonard J. Weisgable, John T. Buturla, Steve M Pignataro
  • Patent number: 9354217
    Abstract: A transport container system for a water analysis sensor cartridge includes a water analysis sensor cartridge configured to be interchangeable. The water analysis sensor cartridge comprises at least two different sensor membranes. A transport container cup comprises, for each of the at least two different sensor membranes, a separate moist chamber. Each separate moist chamber comprises one chamber opening and a specific humectant for each of the at least two different sensor membranes.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: May 31, 2016
    Assignee: HACH LANGE GMBH
    Inventors: Axel Leyer, Lothar Heidemanns, Andreas Jonak, Markus Hahn, Heinz Rudde, Claudia Rieger, Aurelia Stellmach-Hanulok, Andreas Golitz, Michael Kussmann
  • Patent number: 9284534
    Abstract: Compositions, devices, kits and methods are disclosed for assaying cholesterol with a cholesterol oxidase mutant that has been modified at an amino acid residue involved in the active site. The cholesterol oxidase mutant has reduced oxidase activity while substantially maintaining its dehydrogenase activity.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 15, 2016
    Assignees: Ultizymer International, Ltd., Roche Diabetes Care, Inc.
    Inventors: Katsuhiro Kojima, Kazushige Mori, Sode Koji
  • Patent number: 9212380
    Abstract: A reagent layer of a sensor contains as a mediator a quinone compound having a hydrophilic functional group, phenanthrenequinone, and/or a phenanthrenequinone derivative. The quinone compound has a lower redox potential than a conventional mediator, so interfering substances have less effect on detection results with this sensor.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: December 15, 2015
    Assignee: PANASONIC HEALTHCARE HOLDINGS CO., LTD.
    Inventors: Yoshifumi Takahara, Takahiro Nakaminami, Shin Ikeda
  • Patent number: 9207184
    Abstract: In one embodiment, a test strip for testing for cholesterol-related blood analytes in whole blood includes a red blood cell separation layer, the red blood cell separation layer separating red blood cells from a blood sample applied to the test strip as the blood sample flows downward through the red blood cell separation layer. The test strip further includes a reaction layer receiving the blood sample from the red blood cell separation layer, the reaction layer including POE-POP-POE block copolymer, a surfactant, and a reflectivity changing reactant, the POE-POP-POE block copolymers solubilizing essentially only non-LDL cholesterol analytes, the non-LDL cholesterol analytes reacting with the reflectivity changing reactant in order to change a reflectivity of the blood sample.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: December 8, 2015
    Assignee: Polymer Technology Systems, Inc.
    Inventors: Timothy Riley, Aniruddha Patwardhan, Frank LaDuca
  • Patent number: 9145578
    Abstract: This invention provides a method for separately or simultaneously quantifying cholesterol in a total amount of HDL-C, cholesterol in an HDL subfraction of apoE-containing HDL-C, and cholesterol in an HDL subfraction of apoE-deficient HDL-C. The method comprises enzymatically and separately quantifying cholesterol in apoE-containing HDL and cholesterol in apoE-deficient HDL by adding a surfactant selected from the group consisting of a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 0.7 to less than 1.3, a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of less than 0.7, and a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 1.3 or more to a test sample, allowing cholesterol esterase and cholesterol oxidase to react therewith, and quantifying the hydrogen peroxide generated.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: September 29, 2015
    Assignees: Denka Seiken Co., Ltd., National University Corporation Hokkaido University
    Inventors: Yasuki Itoh, Hitoshi Chiba
  • Patent number: 9080201
    Abstract: The present invention provides a method for simply and precisely measuring cholesterol in an HDL subfraction contained in a sample. This is a method for measuring cholesterol in HDL3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than HDL3.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: July 14, 2015
    Assignees: KYOWA MEDEX CO., LTD., KUMAMOTO HEALTH SCIENCE UNIVERSITY
    Inventors: Yuki Katayama, Hiroyuki Sugiuchi, Kazumi Matsushima
  • Patent number: 9051599
    Abstract: Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates. The detectable product is measured at different times after assay initiation. A lipase, cholesterol esterase, cholesterol oxidase and a peroxidase may be used together to produce colored product in amounts directly proportional to the quantity of cholesterol converted. Methods for calculating very-low density lipoprotein cholesterol levels by further including triglyceride measurements are disclosed.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 9, 2015
    Assignee: Theranos, Inc.
    Inventors: Douglas Matje, Ian Gibbons, Paul Patel, Elizabeth A. Holmes
  • Publication number: 20150111234
    Abstract: A portable, hand-held glucose testing device includes a housing configured to accommodate a plurality of test sensors in a stacked arrangement and having a wall with an opening defined therein. A plurality of packaged test sensors is stacked in alignment with one another within the housing. Each of the test sensors is packaged within a blister package. The blister package includes a blister package housing and a cover foil overlying a surface of the blister package housing and the test sensor. A drive slide is configured to displace one of the plurality of packaged test sensors out of alignment with other packaged test sensors. A knife mechanism is configured to pierce through the cover foil, and to engage and urge the test sensor to extend through the opening for receiving a sample. A meter contact is configured to engage the test sensor when the test sensor extends through the opening.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Steven C. Charlton, Allen Brenneman
  • Patent number: 9005985
    Abstract: This invention provides compositions that have a light emitting reporter linked to biomolecules, preferably, nucleotide oligomers. The light reporter particles are silylated and functionalized to produce a coated light reporter particle, prior to covalently linking the biomolecules to the light reporter particle. The light reporter particles of the invention can be excited by a light excitation source such as UV or IR light, and when the biomolecule is DNA, the attached DNA molecule(s) are detectable by amplification techniques such as PCR.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 14, 2015
    Assignee: APDN (B.V.I.) Inc.
    Inventors: Thomas Kwok, Benjamin MingHwa Liang, Stephane Shu Kin So
  • Publication number: 20150079616
    Abstract: Provided is a method for separately or simultaneously quantifying whole HDL-C and cholesterol in HDL subfractions: ApoE-Containing HDL-C and ApoE-deficient HDL-C. A method for enzymatically and separately quantifying cholesterol in the ApoE-deficient HDL comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative to a test sample in a final concentration of 0.05 to 0.10%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated. A method for enzymatically and separately quantifying cholesterol in ApoE-Containing HDL comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative so as to obtain a final concentration of 0.15 to 0.75%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated.
    Type: Application
    Filed: April 10, 2013
    Publication date: March 19, 2015
    Applicants: Denka Seiken Co., Ltd., National University Corporation Hokkaido University
    Inventors: Yasuki Itoh, Hitoshi Chiba
  • Publication number: 20150071857
    Abstract: A unified homeostatic system of cholesterol and steroid hormone pathways is described, in which the uses or modulations of function of the homeostatic system of cholesterol and steroid hormone pathways are linked by lipoproteins, and are used or modulated to achieve a therapeutic benefit, to diagnose a disease or medical condition in humans, or to develop suitable active agents or combinations of active agents. Pharmaceutical compositions, methods of treatment, methods of drug development, and assay methods that rely on the new understanding of the homeostatic system are described.
    Type: Application
    Filed: March 5, 2013
    Publication date: March 12, 2015
    Inventor: Lin Zhi
  • Patent number: 8969525
    Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: March 3, 2015
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
  • Publication number: 20150031058
    Abstract: Methods of the invention involve determining a patient's compliance with a cholesterol lowering therapy. In certain aspects, the invention provides methods that involve conducting a first assay to determine a cholesterol biomarker level in a first sample from a patient prior to the patient undergoing a cholesterol lowering therapy. The methods may also involve conducting a second assay to determine a cholesterol level in a second sample obtained from the patient after the patient has started undergoing a cholesterol lowering therapy. Additionally, the methods involve associating the cholesterol level and the cholesterol biomarker level in which the association allows for the determination of the patient's compliance with the cholesterol lowering therapy.
    Type: Application
    Filed: July 24, 2013
    Publication date: January 29, 2015
    Applicant: BOSTON HEART DIAGNOSTICS CORPORATION
    Inventor: Ernst J. Schaefer
  • Publication number: 20150024392
    Abstract: An object of the present invention is to provide a biosensor comprising a hydrogel capable of immobilizing a physiologically active substance thereon, which can be produced conveniently by use of a safe material, and a method for producing the same. The present invention provides a method for producing a biosensor, which comprises bringing a polymer containing an activated carboxyl group into contact with a substrate surface coated with an organic layer having an amino group to thereby bind the polymer to the organic layer.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 22, 2015
    Applicant: FUJIFILM Corporation
    Inventors: Taisei Nishimi, Toshihide Ezoe, Koji Kuruma, Masayuki Kawakami
  • Patent number: 8932865
    Abstract: A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 having: Step 1 wherein a surfactant that reacts with lipoproteins other than high-density lipoprotein 3 is reacted with a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 in which cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: January 13, 2015
    Assignee: Denka Seiken Co., Ltd.
    Inventors: Maiko Higuchi, Yasuki Itoh
  • Publication number: 20150005351
    Abstract: Methods are disclosed for determining a patient's risk for developing Alzheimer's disease and preventing or treating Alzheimer's disease. Kits for assessing a patient's risk of developing Alzheimer's are also provided.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Inventors: Salvador Soriano, Michael Castello
  • Patent number: 8906638
    Abstract: A method for quantifying remnant-like lipoprotein cholesterol in a sample simply and accurately without requiring separation operations, and a kit therefor are disclosed. A method for quantifying cholesterol in a remnant-like lipoprotein in a sample containing different lipoproteins including the remnant-like lipoprotein comprises a step (1) of erasing cholesterol in lipoproteins other than the remnant-like lipoprotein; and a step (2) of quantifying cholesterol in the remaining remnant-like lipoprotein. The step (1) is carried out under an action of a cholesterol esterase having a molecular weight of more than 40 kDa and not having a subunit having a molecular weight of not more than 40 kDa; and the step (2) is carried out under an action of a cholesterol esterase having a molecular weight of not more than 40 kDa or a cholesterol esterase having a subunit having a molecular weight of not more than 40 kDa.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: December 9, 2014
    Assignee: Denka Seiken Co., Ltd.
    Inventor: Yuhko Hirao
  • Publication number: 20140329258
    Abstract: A test strip to assist in determining the concentration of an analyte in a fluid sample comprises a base, at least one tab and a break line. The base includes a capillary channel and a test element. The capillary channel is in fluid communication with the test element. The test element is adapted to receive the fluid sample. The at least one tab is removably attached to the base. The capillary channel extends from the base into a portion of the tab. The break line intersects the capillary channel in which an inlet to the capillary channel is exposed along the break line when the tab is separated from the base.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventor: Roger Fleming
  • Publication number: 20140322735
    Abstract: The present invention provides a method for the assessment of cholesterol esterification through physiologically relevant pathways and incorporates the function of individual subject's endogenous HDL particles. This ex vivo approach avoids the use of an artificial substrate and provides for determination of LCAT activity that includes both the contribution of a subject's endogenous HDL function and endogenous LCAT protein, and is therefore a significant improvement to the biologic relevance.
    Type: Application
    Filed: April 26, 2014
    Publication date: October 30, 2014
    Applicant: VascularStrategies LLC
    Inventors: Steven Adelman, Heidi Collins
  • Patent number: 8865423
    Abstract: A method for fractional measurement of small, dense LDL, which is adaptable for an autoanalyzer, and a reagent for measurement, are provided, making it possible to conduct rapid and convenient analysis with good sensitivity without pretreatment of a specimen. The method for quantitatively determining small, dense LDL cholesterol in a sample comprises the steps of: (1) eliminating cholesterol in LDL other than small, dense LDL in the presence of phospholipase; and (2) quantitatively determining cholesterol in lipoproteins remaining in step (1) above.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: October 21, 2014
    Assignee: Denka Seiken Co., Ltd.
    Inventors: Yasuki Itoh, Miki Fujimura
  • Publication number: 20140308689
    Abstract: This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 16, 2014
    Applicant: Theranos, Inc.
    Inventors: Ian Gibbons, Shaunak Roy, Edmond Ku
  • Patent number: 8859221
    Abstract: An object to be attained by the present invention is to provide a method for conveniently, rapidly, and specifically measuring HDL-C in a specimen by use of inexpensive materials, and to provide a reagent kit for HDL-C detection and a dry analytical element for HDL-C detection. The present invention provides a method for measuring high density lipoprotein cholesterol (HDL-C) in a body fluid test sample, wherein cholesterol esterase derived from Schizophyllum commune or Pseudomonas sp. and cholesterol oxidase derived from Pseudomonas sp. are used to generate hydrogen peroxide from HDL-C, and thereby HDL-C is selectively measured.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: October 14, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Yoshihiko Abe, Nobuhito Masuda, Hiroko Inomata
  • Publication number: 20140302540
    Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 9, 2014
    Inventors: Arne Ludvig Faaren, Frank Frantzen, Arne Kristian Nordhei, Erling Sundrehagen, Lars Ørning
  • Publication number: 20140287444
    Abstract: A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 25, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Mitsuaki YAMAMOTO, Shoko YAMAMOTO, Mitsuhiro NAKAMURA, Kazunori SAITO
  • Patent number: 8841131
    Abstract: A cholesterol-level measuring apparatus including a portable body having a cholesterol level detecting means for identifying a cholesterol level in a blood sample, and a display screen communicatively coupled to the cholesterol level detecting means for illustrating a learned cholesterol level in the blood sample. Notably, the cholesterol level detecting means includes a disposable test strip having a color-changing reactive reagent that changes color in response to the learned cholesterol level in the blood sample.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: September 23, 2014
    Inventor: Ifeanyi Nzeribe
  • Publication number: 20140255960
    Abstract: An extended range test strip includes a simple system where the end user can determine the concentration of the analyte at high concentration with a single drop of whole blood. A single drop of blood spreads across a spreading layer and into multiple reagent stacks. Multiple reagent stacks of the test strip may be configured to test for different ranges by adding a peroxide modulator. Readings from multiple reagent stacks producing a colorimetric response may be tested simultaneously. Working from the lowest range to the highest range of reagent stacks, the first reagent stack to be less than its maximum range is considered to be the reagent stack that is producing a colorimetric response related to the actual amount of analyte in the sample.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicant: POLYMER TECHNOLOGY SYSTEMS, INC.
    Inventors: Aniruddha Patwardhan, Gary L. Hughes, William Benedict
  • Publication number: 20140255959
    Abstract: Compositions, devices, kits and methods are disclosed for assaying cholesterol with a cholesterol oxidase mutant that has been modified at an amino acid residue involved in the active site. The cholesterol oxidase mutant has reduced oxidase activity while substantially maintaining its dehydrogenase activity.
    Type: Application
    Filed: February 24, 2014
    Publication date: September 11, 2014
    Applicants: Ultizyme International, Ltd., Roche Diagnostics Operations, Inc.
    Inventors: Katsuhiro Kojima, Kazushige Mori, Sode Koji
  • Publication number: 20140234349
    Abstract: The present invention regards nanoparticles comprising a sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 21, 2014
    Inventors: Bror Morein, Saideh Berenjian, Kafei Hu
  • Publication number: 20140220608
    Abstract: A colorimetric reagent in the form of nanoparticles, composite nanoparticles, and nanoparticle coatings, including methods of use, methods of preparation, deposition, and assembly of related devices and specific applications. The colorimetric reagent comprises cerium oxide nanoparticles which are used in solution or immobilized on a solid support, either alone or in conjunction with oxidase enzymes, to form an active colorimetric component that reacts with an analyte to form a colored complex. The rate of color change and the intensity of the color are proportional to the amount of analyte present in the sample. Also described is the use of ceria and doped ceria nanoparticles as an oxygen storage/delivery vehicle for oxidase enzymes and applications in biocatalytic processes in anaerobic conditions of interest in biomedicine and bioanalysis.
    Type: Application
    Filed: April 3, 2014
    Publication date: August 7, 2014
    Applicant: CLARKSON UNIVERSITY
    Inventors: Emanuela Silvana Andreescu, Maryna Ornatska, Cristina R. Ispas, Daniel Andreescu